Vimta Labs experienced a 7.3% increase in share price following impressive FY26 results, with revenue reaching an all-time high of ₹416.3 crore and Profit After Tax (PAT) growing by 16%. The growth was primarily driven by increased demand for pharmaceutical and food testing services.

Vimta Labs reported a quarterly income of ₹1.12 billion and EPS of ₹4.7 for Q4 FY26, with an annual income of ₹4.16 billion. The profit after tax margin remained around 19%, while the earnings before interest, taxes, depreciation, and amortization (EBITDA) margin stayed at 36%. Notably, Q4 capital expenditure was ₹271 million, indicating ongoing investments.

Vimta Labs demonstrates a strong finish to the fiscal year as net profit jumps by 15.2% Year-on-Year, reaching ₹211 million in Q4, compared to ₹183.2 million in the same quarter last year. Additionally, revenue experienced a significant boost of 16.4%, ending at ₹1.1 billion for Q4, up from ₹944.4 million.

Vimta Labs has announced a significant 15.2% increase in its Q4 profits, marking a noteworthy improvement in their financial performance for the fiscal year ending in March 2026.

Vimta Labs announces a dividend of INR 2 per share, distributing some earnings to its shareholders.

Investors are advised to hold onto their shares in Trent, IndiGo, and Vimta Labs, while keeping a close eye on resistance levels. On the other hand, GAIL stocks are suggested for gradual selling, while Voltamp is recommended for gradual buying at current prices.